Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

October 12, 2017: By Jon Swedien

NicoxNicox and pSivida have agreed to potentially combine Nicox’s nitric oxide (NO)-donating compounds with pSivida’s bioerodible sustained-release drug delivery system to develop an IOP-lowering treatment for glaucoma and ocular hypertension, the companies announced Oct. 10.

Nicox and pSivida will collaborate on the selection of NO-donating product candidates from Nicox’s research portfolio to combine with pSivida’s technology. pSivida will be responsible for initial development activities and receive undisclosed payments from Nicox, the companies said.

pSividaThe firms may elect to conduct more detailed nonclinical studies to generate preclinical data and evaluate additional compounds. Nicox would make additional payments for any incremental development activities for each product candidate selected by Nicox to advance, the companies said.

New intellectual property from the collaboration will be jointly owned, the companies said. Nicox and pSivida will negotiate a separate license agreement for any product candidate they plan to commercialize under the collaboration, they said.

Expected payments from Nicox associated with this agreement are not considered material to Nicox’s financial statements at this time, the company said.

Nicox is an international ophthalmic company based in Paris. pSivida, headquartered in Watertown, Massachusetts, is focused on sustained-release drug products for treating eye diseases.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022